MetaCure, the medical technology business focussed on diabetes devices, is looking at annual revenue of $20 million following the roll-out of its flagship product, the company’s founder Professor Shlomo Ben-Haim said in an exclusive interview to The Pharma Letter. 8 September 2015
Autifony Therapeutics, a UK-based biotech company specializing in hearing loss and tinnitus, has appointed John Hutchison as chief medical officer. 3 September 2015
ACADIA Pharmaceuticals has submitted a New Drug Application to the US Food and Drug Administration seeking approval for Nuplazid (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. 3 September 2015
Research and drug development collaborations have been a swelling up in the recent months as companies look to pick up strategic partnerships in a bid to expand the base for research. 2 September 2015
UK drug delivery company SkyePharma has reported robust interim results showing the company’s first half of 2015 operating profits to be 118% ahead year-on-year. 26 August 2015
Anglo-Swedish drug major AstraZeneca has appointed Sean Bohen as executive vice president of global medicines development and chief medical officer. 24 August 2015
If all goes according to plan, Merck Serono may be looking at two new drug launches in the cancer segment as soon as end-2016, the company’s R&D chief Luciano Rossetti said in an exclusive interview with The Pharma Letter. 17 August 2015
Rare disease market has renewed interest from the pharma companies as is visible in the heated merger and acquisition activity in the sector. 10 August 2015
Germany’s Merck KGaA named Isabel De Paoli head of group communications effective March 9, 2016. She will succeed Walter Huber, who is set to retire in March next year. 30 July 2015
Pharma giant Merck & Co on Tuesday said it has agreed to buy Israel-based drugmaker cCAM Biotherapeutics for as much as $605 million in a bid to expand its immuno-oncology portfolio. 29 July 2015
US biotech major Gilead Sciences on Tuesday named William Lee the executive vice president (EVP) for research, and Brett Pletcher the EVP and general counsel. Both Mr Lee and Mr Pletcher will join the company’s senior leadership committee. 28 July 2015
Privately-held pharma company Otic, focused on ear, nose and throat disorders, has appointed Gregory Flesher as chief executive and member of the board. 27 July 2015
Specialist cancer diagnostic medtech company Angle PLC says its loss for the financial year was “deliberate” as it posted a loss from continuing operations of £3.9 million ($6 million). 24 July 2015
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024